The company’s exhibitions will be focused in the areas of its pipeline, proprietary capsid engineering, and manufacturing. Thousand Oaks, Calif.-based Capsida Biotherapeutics (Capsida) has announced ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

ASGCT–OTXL joint venture platform goes live with demo at ASGCT 2026 Annual Meeting and applications opening this month for qualified Asset listings The platform is being demonstrated live during the ...

– NociPro enables highly selective nociceptor targeting and potent NaV1.7 knockdown in rodents and non-human primates, supporting development candidate ETX301 for post‑amputation neuroma pain – – ...

NEW YORK, May 11, 2026 /PRNewswire/ -- Myrtelle, Inc., a clinical-stage gene therapy company selected by the FDA for the START Pilot Program and focused on developing treatments for neurodegenerative ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. NEW ORLEANS — Greetings from ASGCT, where ...

Hans-Peter Kiem, MD, PhD, who holds the Stephanus Family Endowed Chair for Cell and Gene Therapy, has been awarded the 2026 George Stamatoyannopoulos Mentorship Award by the American Society of Gene ...

The American Society of Gene and Cell Therapy (ASGCT) is the primary professional membership organization for gene and cell therapy. The Society's members are scientists, physicians, patient advocates ...

More than 10,000 known rare diseases affect over 30 million people in the United States. However, treatment options have been restricted due to small patient populations and limited commercial ...

Data demonstrate proprietary X-Editors engineered using Scribe’s CRISPR by Design™ approach are a promising gene editing platform for developing genetic medicines with high activity, specificity and ...

- ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma - - Expands pipeline ...